Nivolumab,Ipilimumab
BMS
['niche,(-niche 2),(-niche-2),(-niche2)', 'colorectal', 'rectal']
impressive results from the niche trial, presented at #esmo22 neoadjuvant immunotherapy in mmr deficient localized #colorectal #cancer 
Research Associate at IRB Barcelona working on Cancer Research. Personal account. Views are my own. RT not necessarily endorsement. https://t.co/4jJN0EfA1Y